.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Advanced Soft-Tissue Sarcoma: Integrating Monoclonal Antibody Therapy

EP. 1: Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

EP. 2: Multidisciplinary Care of STS

November 8th 2016

EP. 3: FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

EP. 4: Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

EP. 5: Practical Implications of Using Olaratumab in Patients with STS

November 8th 2016

EP. 6: OS vs PFS with Olaratumab

November 8th 2016

EP. 7: Appropriate Patients for Olaratumab + Doxorubicin

November 8th 2016

EP. 8: Sequencing with Olaratumab in STS

November 8th 2016

EP. 9: Toxicity of Olaratumab and Doxorubicin

November 8th 2016

EP. 10: Final Thoughts on STS

November 8th 2016